PTC Therapeutics Inc
PTCT
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
63.6% downsideOvervalued by 63.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.55 Billion |
|---|---|
| Enterprise Value | $6.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $8.58 |
| Beta | 0.55 |
| Outstanding Shares | 82,521,023 |
Return
| Return on Equity | 103.47% |
|---|---|
| Return on Assets | -6.51% |
| Return on Invested Capital | -3.70% |
Valuation & Multiples
| P/E Ratio | -34.9 |
|---|---|
| PEG | 34.79 |
| Price to Sales | 8.21 |
| Price to Book Ratio | -27.38 |
| Enterprise Value to Revenue | 7.39 |
| Enterprise Value to EBIT | -84.95 |
| Enterprise Value to Net Income | -33 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | -2.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1743▼ 56.88% |
|---|---|
| Total Calls | 799,900▲ 201.39% |
| Total Puts | 139,400▼ 29.31% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 118.35%▲ 4.59% |
|---|---|
| Total Invested | $6.51B▼ 7.61% |
| Investors Holding | 358▼ 5.00% |
ESG Score
No data
About PTC Therapeutics Inc
CEO: Stuart Peltz Relevant Senate Committees
Regulates Medicare and Medicaid reimbursement policies. Decisions made here regarding the Inflation Reduction Act and drug pricing directly dictate PTCT's revenue potential.
Directly oversees the FDA and the drug approval process. Committee members have insight into regulatory hurdles and clinical trial requirements that determine PTCT's success.
Jurisdiction over intellectual property and antitrust laws is critical for pharma companies; patent protection is the primary driver of PTCT's valuation.
The committee's focus on drug pricing and specialty pharmacy services creates significant headline risk and potential for legislative scrutiny regarding PTC's orphan drug prices.